Aktienanalyse zu Vaxcyte Inc (PCVX)PCVXVaxcyte Inc

Vaxcyte, Inc. is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company's pipeline includes VAX-31, VAX-24 and VAX-XL. VAX-31, a 31-valent PCV candidate being evaluated in the OPUS Phase III adult clinical program and in a Phase II infant clinical program, is being developed for the prevention of IPD and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. VAX-XL leverages the Company’s carrier-sparing, site-specific conjugation technology. It is re-engineering the way highly complex vaccines are made through XpressCF, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections, and VAX-GI, a vaccine candidate designed to prevent Shigella. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Vaxcyte Inc (PCVX) is a good buy right now due to its recent positive Phase 3 trial results for the VAX-31 vaccine, which led to a significant 60% stock surge, and analysts projecting a price target as high as $163, well above the current price of $60.43. The stock has shown a year-to-date increase of 30.07%, reflecting strong market interest and potential profitability. However, the main risk is the negative earnings trend, with projected EPS of -1.84 for the next earnings report, indicating ongoing financial challenges.